U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07291063) titled 'Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA' on Dec. 02.
Brief Summary: This study is a prospective, observational study designed to analyze the safety, tolerability, and efficacy of first-line treatment using the combination of gemcitabine and cisplatin plus anti-PD-1/PD-L1 antibodies for patients with advanced cholangiocarcinoma.
Study Start Date: July 19, 2024
Study Type: OBSERVATIONAL
Condition:
Cholangiocarcinoma
Intervention:
DRUG: Anti-PD-1/PD-L1 antibody
Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
DRUG: Gemcitabine and Cisplatin Chemotherapy
Gemcitabine and cisplatin In...